Strategic Partnership for Domestic Distribution of Immune-Boosting Vaccine "Fluad" and Cell-Based Vaccine "Flucelvax"
Samjin Pharmaceutical announced on the 18th that it has signed a strategic sales partnership agreement with global vaccine company CSL Seqirus Korea for the domestic distribution of the adjuvanted influenza vaccine 'Fluad® Quad Prefilled Syringe' and the cell-based influenza vaccine 'Flucelvax® Quad'.
Sangjin Kim, President of Samjin Pharmaceutical (right), and Kisung Yoo, CEO of CSL Seqirus Korea, are posing for a commemorative photo after holding a strategic sales partnership agreement ceremony on the 17th. Samjin Pharmaceutical
Samjin Pharmaceutical explained that this agreement aims to provide more patients with access to CSL Seqirus Korea's influenza vaccines. The company expects that the synergy created by combining its domestic sales and marketing network with CSL Seqirus Korea's global vaccine leadership will be significant.
Under the agreement, Samjin Pharmaceutical will be responsible for the marketing and promotion of Fluad and Flucelvax, and will jointly handle domestic distribution with CSL Seqirus Korea, which is in charge of vaccine importation.
With the main flu vaccination season approaching, Samjin Pharmaceutical plans to strengthen education and communication with healthcare professionals by organizing academic conferences, symposiums, and online seminars through specialized channels. The company also intends to actively conduct advertisements and campaigns targeting the general public, thereby raising awareness of the importance of vaccination and increasing recognition of CSL Seqirus Korea's premium vaccines.
Fluad is an influenza vaccine containing the adjuvant MF59®, and was approved by the Ministry of Food and Drug Safety in September 2022 for the prevention of influenza in people aged 65 and older, who often fail to develop sufficient immune responses after vaccination. It can induce a stronger immune response than standard vaccines and maintain long-term preventive effects for up to one year.
Flucelvax is the world's first cell-based influenza vaccine and was approved by the Ministry of Food and Drug Safety in August last year for the prevention of influenza in children aged two years and older and in adults. While conventional egg-based manufacturing methods can cause the virus to adapt and mutate during production, Flucelvax uses cell culture technology to increase the antigenic match with the influenza virus. It can also be safely administered to patients with severe egg allergies, and has demonstrated higher effectiveness compared to standard egg-based vaccines through 'Real World Effectiveness' clinical studies. Flucelvax is scheduled for domestic launch in the 2025-2026 season, and it is expected that its indication will be expanded to include the prevention of influenza in children and adults aged six months and older before actual administration begins.
Sangjin Kim, President of Samjin Pharmaceutical, stated, "This collaboration marks a turning point for us to expand our business scope beyond treatment-focused areas into the preventive vaccine sector."
Kisung Yoo, CEO of CSL Seqirus Korea, said, "Through this agreement, we expect to supply differentiated influenza vaccines, Fluad and Flucelvax, to a greater number of people. We will continue to work closely with Samjin Pharmaceutical to contribute to the improvement of public health in Korea."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
